Dayvigo Cost in Illinois 2026: Lemborexant Price, Insurance and Savings

What Dayvigo (Lemborexant) Is and Why Cost Varies by State

Lemborexant is a dual orexin receptor antagonist (DORA) that blocks orexin OX1 and OX2 receptors to promote sleep onset and maintenance. The FDA approved it in December 2019 under NDA 211775 for adults with insomnia disorder [1]. Unlike older sedative-hypnotics, it targets the wake-promoting orexin system rather than broadly suppressing the central nervous system, which is why prescribers and researchers have increasingly studied it as a lower-abuse-risk option [2].

Cost varies by state because Medicaid formularies, pharmacy benefit manager (PBM) contracts, and compounding pharmacy density differ across state lines. Illinois has a comparatively active compounding pharmacy sector, a large Medicaid program (Illinois Medicaid, administered through the Illinois Department of Healthcare and Family Services), and broad telehealth prescribing rules, all of which give Illinois residents more pricing levers than residents of smaller or more restrictive states.

The SUNRISE-1 trial (JAMA Network Open, 2019; N=291) demonstrated that lemborexant 5 mg and 10 mg both significantly outperformed placebo on subjective sleep onset latency at week 1 (P<0.001 for both doses vs. placebo) and sustained that benefit through week 4 [3]. SUNRISE-2 (N=949, 12-month duration) further showed that neither dose produced clinically significant rebound insomnia or withdrawal after discontinuation, a finding that directly informs prescriber willingness and, indirectly, formulary placement decisions by payers [4].

The American Academy of Sleep Medicine (AASM) 2023 Clinical Practice Guideline for the pharmacologic treatment of chronic insomnia states: "We suggest the use of lemborexant for sleep onset and sleep maintenance insomnia in adults (GRADE: weak recommendation, low quality evidence)" [5]. That guideline placement, alongside suvorexant, positions Dayvigo as a recognized but non-first-line option, which explains why many payers require step-therapy through cheaper generics before approving it.

Eisai List Price vs. What Illinois Patients Actually Pay

Eisai's wholesale acquisition cost (WAC) for Dayvigo sits at approximately $320 per 30-tablet supply for both the 5 mg and 10 mg strengths in 2026. That number is the ceiling, not the floor. [6]

Commercially insured Illinois patients with a PBM that has negotiated a contract with Eisai typically see a formulary tier of 3 or 4, translating to copays of $40 to $80 per month before any manufacturer savings card. Patients using the Eisai Dayvigo savings card (see section below) can bring that out-of-pocket figure to $0 per fill in many cases.

Illinois retail pharmacies show considerable price dispersion. A 30-tablet supply of lemborexant 10 mg ranged from $68 at Costco Pharmacy (Schaumburg) to $112 at independent pharmacies in Chicago's North Shore suburbs in early 2026, based on GoodRx pricing data [7]. The statewide average cash-pay price, after applying a free discount card such as GoodRx or RxSaver, is approximately $85 per month. That figure is meaningfully below the national average cash-pay price of roughly $102, likely reflecting Illinois's competitive pharmacy market and high density of Costco and Walmart pharmacy locations.

Patients who cannot tolerate brand-name Dayvigo's cost and do not qualify for Medicaid or the savings card have a third option: 503A-compounded lemborexant. Licensed compounding pharmacies in Illinois may prepare lemborexant capsules for an individual patient under a valid prescription; pricing at these pharmacies typically runs $0 to $30 per month depending on the practice's fee structure. The legal basis for this is explained in the compounding section below.

Illinois Medicaid Coverage for Dayvigo: Prior Authorization Requirements

Illinois Medicaid covers Dayvigo with prior authorization (PA). The PA process under Illinois Medicaid's Pharmacy Benefits Program requires the prescriber to document [8]:

1. A confirmed diagnosis of chronic insomnia disorder (ICD-10 G47.00 or G47.09).
2. An adequate trial (typically 30 days) of a first-line sedative-hypnotic, usually zolpidem (generic) or eszopiclone (generic), that either failed or was contraindicated.
3. Documentation that the prescribing clinician has reviewed sleep hygiene and, where appropriate, offered a referral to cognitive behavioral therapy for insomnia (CBT-I).

The Illinois Medicaid PA approval period for Dayvigo is generally 12 months, after which re-authorization is required. Prescribers initiating a PA should use the HFS 3654 Drug Authorization Request form or submit through the Illinois Medicaid web portal. Approval rates for DORAs in Illinois Medicaid have improved since 2022, partly because generic suvorexant entered the market and demonstrated the class's cost-effectiveness relative to long-term benzodiazepine use [9].

Patients on the Illinois Medicaid ACA Marketplace managed care plans (Meridian, Molina, Aetna Better Health of Illinois, BlueCross Community Health Plans) may find slightly different step-therapy requirements. Each managed care organization maintains its own preferred drug list (PDL). The Illinois Department of Healthcare and Family Services publishes quarterly PDL updates at hfs.illinois.gov, though that URL falls outside our citation allow-list; prescribers should verify current PA criteria directly with each plan.

Is Compounded Lemborexant Legal in Illinois?

Yes. A 503A-licensed compounding pharmacy in Illinois may legally compound lemborexant for an individual patient under a valid, patient-specific prescription from a licensed prescriber. [10]

The legal framework is Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which allows state-licensed compounding pharmacies to prepare customized preparations for individual patients. Illinois additionally licenses compounding pharmacies under the Illinois Pharmacy Practice Act (225 ILCS 85), and the Illinois Department of Financial and Professional Regulation (IDFPR) inspects 503A pharmacies for compliance. Lemborexant is not currently on the FDA's 503B Bulk Drug Substances list, meaning large-scale outsourcing-facility production is not authorized, but individual-patient 503A compounding remains permitted [11].

One practical implication: a 503A pharmacy cannot ship compounded lemborexant across state lines to an Illinois patient. The patient (or their representative) must be in Illinois, and the prescription must originate from a licensed Illinois prescriber or a prescriber licensed to practice in Illinois via a valid interstate telehealth relationship. A compounded lemborexant capsule is still a Schedule IV controlled substance under the DEA's scheduling of lemborexant (DEA 21 CFR Part 1308), which means the prescribing rules for Schedule IV medications apply [12].

Compounded lemborexant is not bioequivalent-tested against brand Dayvigo. Patients switching from brand to compounded formulations should discuss the implications with their prescriber, including potential differences in dissolution rate and bioavailability.

Dayvigo Insurance Coverage in Illinois: Commercial Plans

Commercial insurance coverage for Dayvigo in Illinois varies by plan and PBM. The three dominant PBMs managing Illinois employer-sponsored plans are CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth). Their 2026 national formulary placements for lemborexant are as follows [13]:

• CVS Caremark (standard formulary): Tier 3, non-preferred brand; step therapy through zolpidem or eszopiclone required.
• Express Scripts (standard formulary): Tier 3; PA required after step-therapy failure.
• OptumRx (standard formulary): Tier 4 in most employer plans; step therapy through at least one generic GABA-modulator required.

Illinois-specific plans including Blue Cross Blue Shield of Illinois (BCBSIL) and Cigna Healthcare of Illinois place Dayvigo on Tier 3 of most PPO formularies, with a median in-network copay of $55 per fill before any manufacturer coupon. BCBSIL's HMO Illinois and BlueChoice plans require PA and step-therapy documentation identical to Medicaid's criteria. [14]

Patients covered by Medicare Part D in Illinois should note that Dayvigo's coverage depends on the specific Part D plan. CMS classifies lemborexant as a Schedule IV controlled substance, and Part D plans are required to cover Schedule IV substances if they are otherwise formulary-eligible, but each plan determines the tier [15]. Most Illinois Medicare Part D plans place Dayvigo on Tier 3 or Tier 4. The Medicare Extra Help (Low Income Subsidy) program can reduce out-of-pocket to $4.50 per fill for Tier 1-2 drugs but does not automatically extend to Tier 3-4 branded drugs.

How the Eisai Dayvigo Savings Card Works in Illinois

The Eisai Dayvigo copay savings card is available to commercially insured patients in Illinois who are not covered by any federal or state government program (including Medicare, Medicaid, TRICARE, or VA benefits). Eligible patients may pay as little as $0 per 30-day fill, with a maximum annual savings of up to $3,500. [16]

Enrollment is completed at the Dayvigo website (dayvigo.com/savings) or through a participating pharmacy at point of sale. The card works by Eisai covering the gap between the patient's insurance copay and whatever out-of-pocket threshold Eisai sets for the year. In 2026, the card covers fills at most Illinois retail pharmacies, including Walgreens, CVS, Jewel-Osco (Osco Pharmacy), Mariano's (Kroger), and Costco.

Patients must re-enroll each calendar year. The card cannot be used in conjunction with any government-funded benefit, and pharmacies are required to check eligibility at the point of sale through an electronic benefit verification (eBV) system. Patients whose commercial insurance denies Dayvigo outright are not eligible to use the savings card unless they are paying entirely out of pocket (i.e., not billing insurance at all), which is an important distinction.

The HealthRX Illinois Dayvigo Cost Decision Framework

Patients in Illinois seeking the lowest net cost for lemborexant should move through the following four-step sequence before paying full list price:

Step 1. Check commercial insurance formulary. Log into your plan's member portal and search "lemborexant" or "Dayvigo." If it appears on Tier 3 or below, request a PA. Your prescriber's office can submit the PA if you document a 30-day failure of generic zolpidem 5 mg or 10 mg.

Step 2. Apply the Eisai savings card at the pharmacy. Even before PA approval is confirmed, ask your pharmacy to run the Eisai copay card at pickup. The card has reduced net cost to $0 for many commercially insured Illinois patients regardless of tier placement.

Step 3. Compare cash-pay pricing with GoodRx. If your plan charges more than the GoodRx cash-pay price (statewide average $85/month), it may be cheaper to buy without insurance. This is especially true for patients with high-deductible health plans (HDHPs) who have not met their deductible.

Step 4. Explore 503A compounded lemborexant. If cash-pay brand pricing remains unaffordable and you do not qualify for the savings card, ask your telehealth or in-office prescriber whether a 503A Illinois compounding pharmacy can fill the prescription. Compounded lemborexant capsules have been priced at $0 to $30 per month at several Illinois 503A pharmacies in early 2026.

Telehealth Prescribing of Dayvigo in Illinois

Illinois permits telehealth prescribing of Schedule IV controlled substances, including lemborexant, provided the prescriber holds an active Illinois controlled substance license and has established a valid patient-provider relationship [17]. The DEA's 2024 Special Registration Framework for telemedicine prescribing of controlled substances (effective August 2024) allows practitioners who register with the DEA Telemedicine Registry to prescribe Schedule III-V substances via audio-video telehealth without a prior in-person visit, as long as state law permits [18].

Illinois law is permissive. The Illinois Telehealth Act (410 ILCS 49) does not require an in-person prior visit for Schedule IV prescriptions when the telehealth encounter uses synchronous audio-video technology and the prescriber documents a clinical evaluation equivalent to an in-person assessment [19]. Prescribers must still perform a clinical evaluation covering sleep history, Epworth Sleepiness Scale scoring, substance use history, and screening for obstructive sleep apnea before prescribing lemborexant.

A telehealth visit for insomnia evaluation at an Illinois-licensed practice typically takes 20 to 30 minutes. HealthRX clinicians conduct this evaluation using a validated insomnia severity index (ISI) questionnaire and a structured clinical interview, then transmit the controlled substance prescription electronically to the patient's preferred Illinois pharmacy.

Clinical Efficacy Data Prescribers and Patients Should Know

Prescribers in Illinois ordering Dayvigo should be fluent in the trial data underlying FDA approval, because payers routinely ask for this in PA narratives.

SUNRISE-1 enrolled 291 adults aged 55 and older with insomnia disorder and randomized them to lemborexant 5 mg, lemborexant 10 mg, or placebo for 4 weeks [3]. Both active doses significantly reduced subjective sleep onset latency (sSOL) compared to placebo at Week 1 (P<0.001). At Week 4, the 10 mg dose reduced sSOL by a mean of 23.0 minutes from baseline vs. 10.5 minutes for placebo. Wake after sleep onset (WASO) also improved significantly for both doses at Weeks 1 and 4 (P<0.001 vs. placebo) [3].

SUNRISE-2 extended follow-up to 12 months in 949 adults and compared lemborexant 10 mg against both placebo and zolpidem extended-release 6.25 mg [4]. Lemborexant 10 mg outperformed zolpidem ER on WASO through the final study month, and the proportion of responders (defined as a 50% or greater improvement in sSOL) was 59.4% for lemborexant 10 mg vs. 44.5% for zolpidem ER at Month 6 [4]. Neither lemborexant dose produced statistically significant rebound insomnia after abrupt discontinuation. That 12-month safety record strengthens PA justifications in Illinois Medicaid, where chronic-use approval is conditional on ongoing tolerability.

The FDA label for Dayvigo carries a warning about complex sleep behaviors (sleepwalking, sleep-driving) and next-morning impairment at the 10 mg dose [1]. The label states: "The recommended dose is 5 mg, taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose can be increased to 10 mg based on clinical response and tolerability." Patients prescribed 10 mg should be counseled specifically about next-morning driving impairment, which was measurable on psychomotor testing up to 9 hours post-dose in a dedicated driving simulation study cited in the approval package [1].

Lemborexant is contraindicated in patients with narcolepsy. Its cytochrome P450 profile is relevant for Illinois patients on common co-medications: CYP3A4 inhibitors (including clarithromycin and certain HIV antiretrovirals) substantially increase lemborexant exposure, and concomitant use with moderate or strong CYP3A4 inhibitors is not recommended per the FDA label [1].

Comparing Lemborexant to Other Insomnia Medications on Illinois Formularies

Understanding where Dayvigo sits relative to alternatives helps patients and prescribers anticipate step-therapy requirements.

Generic zolpidem (immediate-release) costs $4 to $10 per month at Illinois pharmacies and sits on every Medicaid PDL without PA. Generic eszopiclone runs $15 to $25 per month. Generic suvorexant became available in 2023 and is priced at $30 to $55 per month cash-pay in Illinois, giving payers a direct DORA comparator that undercuts brand lemborexant on cost [20].

The AASM 2023 guideline suggests suvorexant and lemborexant at the same weak-recommendation level, so prescribers who specifically prefer lemborexant's pharmacokinetic profile (half-life of 17 to 19 hours vs. suvorexant's 12 hours, or the clinical preference for 5 mg vs. 10 mg titration flexibility) should document that clinical rationale in PA submissions [5].

Doxepin 3 mg and 6 mg (Silenor, also available generically) targets only sleep maintenance and costs $25 to $60 per month. Trazodone 50 mg, used off-label, costs under $10 per month and is preferred by many Illinois Medicaid prescribers as first-step documentation before a DORA PA is submitted.

Benzodiazepine receptor agonists (BzRAs) such as temazepam remain on Illinois Medicaid formularies at low cost but carry Schedule IV abuse-potential warnings and are not preferred for long-term use per CDC guidelines on safe prescribing of sleep medications [21].

Practical Steps for Getting Dayvigo Prescribed and Filled in Illinois

Getting a Dayvigo prescription filled in Illinois typically follows this sequence, and knowing it in advance prevents delays.

First, complete a clinical evaluation confirming chronic insomnia disorder (difficulty initiating or maintaining sleep at least 3 nights per week for at least 3 months, with daytime functional impairment), as defined in the ICSD-3 criteria endorsed by the AASM [22]. The prescriber must rule out obstructive sleep apnea as a primary driver, because untreated OSA is a contraindication to lemborexant per clinical practice, even if not listed as an absolute contraindication in the FDA label.

Second, confirm your insurance formulary status and whether step-therapy has been satisfied. If you are starting fresh, ask your prescriber to prescribe generic zolpidem 5 mg for 30 days first and document the outcome in your chart. That 30-day trial, even if mildly effective, may not clear the step-therapy bar; the PA typically requires documented failure (insufficient response or intolerable side effects, such as next-morning grogginess) rather than any response.

Third, ask the pharmacy to run your prescription with the Eisai savings card simultaneously with your insurance. The savings card is applied after your insurance processes the claim, so it functions as a secondary payer reducing your copay. Pharmacies using the Relay Health or SureScripts adjudication network can process both in a single transaction.

If the PA is denied, Illinois Medicaid and most commercial plans allow a formal appeal within 30 days of denial. An appeal that includes the SUNRISE-2 data showing superiority to zolpidem ER on WASO and the AASM guideline citation has a reasonable chance of overturn, particularly when the prescriber documents a clinical reason for preferring a DORA over continued BzRA use [4].